NEW YORK --(BUSINESS WIRE)--Feb. 29, 2024-- Neurogene Inc. (NASDAQ: NGNE) (“Neurogene” or “the Company”), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will
February 29, 2024
DSMB clears third pediatric patient for dosing in ongoing NGN-401 Phase 1/2 clinical trial for Rett syndrome; On track to dose third pediatric patient in early 1Q:24 CTA clearance obtained from UK MHRA for NGN-401 Ended 2023 in a strong financial position with approximately $200 million in cash and
January 5, 2024